Beta
Back to LLY.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
operating-expenses-chart

LLY Operating Expenses

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q4'25, Eli Lilly's (LLY) operating expenses reached a total of approximately 6.93B USD, with R&D expenses at 3.80B USD and SG&A expenses at 3.13B USD, marking the highest quarterly figure in the observed period and reflecting intensified investments in research and administrative functions. From Q1'23 to Q4'25, total operating expenses exhibited a consistent upward trend, growing from 3.73B USD to 6.93B USD, driven by steady increases in both R&D (from 1.99B USD to 3.80B USD) and SG&A (from 1.75B USD to 3.13B USD) categories. R&D expenses showed particularly robust growth, with notable accelerations in 2024 and 2025, including a 39% year-over-year jump from Q4'24 to Q4'25, while SG&A followed a similar but slightly more moderate trajectory, underscoring expanding operational scale amid pharmaceutical innovation demands. The stacked bar chart highlights R&D as the dominant component, consistently comprising over 50% of total expenses throughout the period.